{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:01:57Z","timestamp":1780448517777,"version":"3.54.1"},"reference-count":14,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T00:00:00Z","timestamp":1678233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,5]]},"abstract":"<jats:p>This letter comments on \u2018Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab\u2019.<\/jats:p>","DOI":"10.1093\/ced\/llad082","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T12:09:27Z","timestamp":1678277367000},"page":"701-703","source":"Crossref","is-referenced-by-count":11,"title":["Paradoxical hidradenitis suppurativa induced by adalimumab biosimilar successfully treated with guselkumab in a patient with psoriasis. Comment on \u2018Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab\u2019"],"prefix":"10.1093","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2523-050X","authenticated-orcid":false,"given":"Fabrizio","family":"Martora","sequence":"first","affiliation":[{"name":"Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Fabbrocini","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8401-5730","authenticated-orcid":false,"given":"Claudio","family":"Marasca","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1136-637X","authenticated-orcid":false,"given":"Teresa","family":"Battista","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Megna","sequence":"additional","affiliation":[{"name":"Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II , Naples , Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,3,8]]},"reference":[{"key":"2023100918462278200_llad082-B1","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/ced\/llad003","article-title":"Paradoxical hidradenitis suppurativa due to anti-interleukin-1 agents for mevalonate kinase deficiency successfully treated with the addition of ustekinumab","volume":"48","author":"L\u00f3pez Sanz","year":"2023","journal-title":"Clin Exp Dermatol"},{"key":"2023100918462278200_llad082-B2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.2147\/CCID.S391356","article-title":"Adalimumab, ustekinumab, and secukinumab in the management of hidradenitis suppurativa: a review of the real-life experience","volume":"16","author":"Martora","year":"2023","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2023100918462278200_llad082-B3","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1159\/000521712","article-title":"A case of pemphigus vulgaris and hidradenitis suppurativa: may systemic steroids be considered in the standard management of hidradenitis suppurativa?","volume":"8","author":"Martora","year":"2022","journal-title":"Skin Appendage Disord"},{"key":"2023100918462278200_llad082-B4","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/biomedicines10020455","article-title":"Paradoxical hidradenitis suppurativa during biologic therapy, an emerging challenge: a systematic review","volume":"10","author":"Ruggiero","year":"2022","journal-title":"Biomedicines"},{"key":"2023100918462278200_llad082-B5","doi-asserted-by":"crossref","DOI":"10.2340\/00015555-3844","article-title":"Paradoxical reaction in a patient with hidradenitis suppurativa undergoing adalimumab treatment","volume":"101","author":"Ikeya","year":"2021","journal-title":"Acta Derm Venereol"},{"key":"2023100918462278200_llad082-B6","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2023100918462278200_llad082-B7","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.2147\/CCID.S364640","article-title":"Guselkumab, risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence","volume":"15","author":"Ruggiero","year":"2022","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2023100918462278200_llad082-B8","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1080\/09546634.2019.1654067","article-title":"Guselkumab in the treatment of concomitant hidradenitis suppurativa, psoriasis, and Crohn's disease","volume":"32","author":"Berman","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"2023100918462278200_llad082-B9","first-page":"e140\u20131","article-title":"Guselkumab in the treatment of severe hidradenitis suppurativa","volume":"33","author":"Kovacs","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100918462278200_llad082-B10","doi-asserted-by":"crossref","first-page":"2874","DOI":"10.1002\/ccr3.3090","article-title":"Guselkumab for hidradenitis suppurativa in a patient with concomitant Crohn's disease: report and systematic literature review of effectiveness and safety","volume":"8","author":"J\u00f8rgensen","year":"2020","journal-title":"Clin Case Rep"},{"key":"2023100918462278200_llad082-B11","doi-asserted-by":"crossref","first-page":"e14930","DOI":"10.1111\/dth.14930","article-title":"Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role?","volume":"34","author":"Burzi","year":"2021","journal-title":"Dermatol Ther"},{"key":"2023100918462278200_llad082-B12","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.jdcr.2018.12.002","article-title":"Secukinumab and hidradenitis suppurativa: friends or foes?","volume":"5","author":"Marasca","year":"2019","journal-title":"JAAD Case Rep"},{"key":"2023100918462278200_llad082-B13","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/ced.15291","article-title":"Strategies adopted in a southern Italian referral centre to reduce adalimumab discontinuation: comment on \u2018Can we increase the drug survival time of biologic therapies in hidradenitis suppurativa?\u2019","volume":"47","author":"Martora","year":"2022","journal-title":"Clin Exp Dermatol"},{"key":"2023100918462278200_llad082-B14","doi-asserted-by":"crossref","first-page":"2026","DOI":"10.1111\/ced.15306","article-title":"Management of patients with hidradenitis suppurativa during COVID-19 vaccination: an experience from southern Italy. Comment on: \u2018Evaluating the safety and efficacy of COVID-19 vaccination in patients with hidradenitis suppurativa\u2019","volume":"47","author":"Martora","year":"2022","journal-title":"Clin Exp Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llad082\/49590939\/llad082.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/6\/701\/51961854\/llad082.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/48\/6\/701\/51961854\/llad082.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T18:53:20Z","timestamp":1696877600000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/48\/6\/701\/7072347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,8]]},"references-count":14,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3,8]]},"published-print":{"date-parts":[[2023,6,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llad082","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"value":"0307-6938","type":"print"},{"value":"1365-2230","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,6]]},"published":{"date-parts":[[2023,3,8]]}}}